#ECTRIMS2022 – ATA188 Could Be ‘Game Changing’ for Progressive MS
In an early clinical trial, Atara Biotherapeutics’ investigational treatment ATA188 stabilized or eased disability in most people with nonactive,…
Articles by Lindsey Shapiro, PhD
#ECTRIMS2022 – 3-year Data Show Evobrutinib Safely Lowers Relapses
Long-term use of the investigational BTK inhibitor evobrutinib among people with relapsing forms of multiple sclerosis (MS) continues…
#ECTRIMS2022 – Vumerity Lowers RRMS Activity Over 2 Years
Up to two years of Vumerity (diroximel fumarate) treatment was generally well-tolerated and led to significant decreases in disease activity…
#ECTRIMS2022 – Ocrevus Seems to Beat Rituximab in Reducing Relapses
Ocrevus (ocrelizumab), an anti-CD20 therapy developed by Genentech, seems to be superior to rituximab at lowering relapse rates…
#ECTRIMS2022 – Job Prospects Can Slowly Take a Hit After CIS Diagnosis
In the years after a diagnosis of clinically isolated syndrome (CIS) — a first episode of neurological symptoms suggestive…
#ECTRIMS2022 – DMTs Ease SPMS Disability Early but Not Over Time
Early use of disease-modifying therapies (DMTs) among people with secondary progressive multiple sclerosis (SPMS) may lead to overall…
#ECTRIMS2022 – High-efficacy DMTs Linked to Cervical Cancer Risk
Exposure to high-efficacy disease-modifying therapies (DMTs) is associated with an increased risk of cervical abnormalities in women with…
#ECTRIMS2022 – Genetic Variants Tied to Worse MS ID’d in New Study
Genetic variants in genes mostly active in the brain and spinal cord — the central nervous system — are associated…
#ECTRIMS2022 – ATA188 Still Easing Disability in Progressive MS Patients
The investigational immunotherapy ATA188 continues to ease disability and prevent brain tissue shrinkage in people with progressive forms of…
#ECTRIMS2022 – Smartphone Tap Speed May Help in Monitoring MS
Tap speed — or how quickly one types on a smartphone keyboard — may be a useful tool for monitoring…
#ECTRIMS2022 – EBV Antibodies Precede Early Nerve Damage Signs
An infection with the Epstein-Barr virus (EBV) consistently preceded elevations in neurofilament light chain (NfL), an early biomarker of…
#ECTRIMS2022 – Poor Myelin Repair Offers Clues in Disease Progression
Remyelination, or regeneration of the myelin sheath that’s progressively damaged and lost in multiple sclerosis (MS), may be…
#ECTRIMS2022 – Fertility Treatment Won’t Raise Relapse Risk for Women
Fertility treatments do not significantly increase the risk of relapse in women with multiple sclerosis (MS), even among those…
Maker of PoNS Device for MS Salutes Physical Therapists
For National Physical Therapy Month, Helius Medical Technologies is spotlighting physical therapists who make possible the success of the company’s…
GoodRx Offers MS Patients Digital Vumerity Enrollment Form
GoodRx, in collaboration with Biogen, has made the enrollment form for starting a multiple sclerosis (MS) patient on…
EBV Antibodies Found at Increased Levels in MS Patients in Study
People with multiple sclerosis (MS) are significantly more likely to have antibodies against the Epstein-Barr virus (EBV) — the…
Sexual Dysfunction in MS Real But Often Ignored: Neurologist Survey
Neurologists in Colombia agree that sexual dysfunction is burdensome and affects quality of life in major ways for people…
Virtual Reality Upper Limb Training Feasible for MS Patients: Pilot Study
XRHealth‘s virtual reality (VR) software, which provides an immersive three-dimensional environment where patients do repetitive tasks such as popping…
MS Disease Progression Could Be Monitored With Smell Test: Study
Evaluating a person’s sense of smell may help monitor disease progression in people with multiple sclerosis (MS), according to…
Kesimpta More Effective, Costs Less Than Most DMTs for RRMS: Analysis
Kesimpta (ofatumumab) is more cost-effective for treating relapsing-remitting multiple sclerosis (RRMS) than most other disease-modifying therapies (DMTs)…
Unhealthy Coping Strategies in MS May Lead to Worse Quality of Life
People with multiple sclerosis (MS) may be more likely to use unhealthy or ineffective coping mechanisms than healthy individuals…
Novartis to Petition U.S. Supreme Court to Uphold Gilenya Patent
Novartis said it will petition the U.S. Supreme Court to uphold a patent that protects the dosing regimen of…
Second SPMS Patient Given Foralumab Continues to Improve
Six months of treatment with foralumab nasal spray led to significant functional improvements in the second patient with non-active…
Lower Limb Resistance Training Leads to Upper Limb Strength Gains
Ten weeks of lower limb fast-velocity concentric resistance training (FVCRT) led to muscle strength gains in both the upper and…
Wearable Sensors May Identify MS Patients at Greater Risk of Falls
Using wearable sensors to monitor gait during daily life may be a promising way to identify people with multiple…
Stem Cell Transplant for MS Eases Fatigue, Improves Life Quality
Autologous hematopoietic stem cell transplant (aHSCT) — commonly called stem cell therapy — lessens fatigue and improves quality of…
Inflammatory Brain Lesions Often Don’t Match Relapse Symptoms
More than half of relapsing-remitting multiple sclerosis (RRMS) patients in a small study had active inflammatory brain lesions during…
Understanding MS Burden, Support Needs Can Challenge Couples
Differences are evident in the perceived frequency of expressions of support needs and disease burden between people with multiple…
Progression Without Relapse Also Common in RRMS, Patients Say
Nearly two-thirds of people with relapsing-remitting multiple sclerosis (RRMS) report disease progression independent of relapses, according to a survey…
Immunoadsorption Better Than 2nd Round of Steroids for MS Relapse
A type of blood-cleansing process called immunoadsorption worked better than a second round of methylprednisolone for treating relapse in…